Amphion Innovations plc
Amphion Partner Company, Kromek, Announces First Day of Dealings on AIM

London and New York, 16 October 2013 – Amphion Innovations plc (LSE: AMP) (“Amphion” or the “Company”), the developer of medical and technology businesses, is pleased to announce that Kromek Group plc ("Kromek" or the "Group"), who designs, develops, and produces x-ray imaging and radiation detection products using its core CZT technology for the medical, security screening, and nuclear markets has announced that its shares will today be admitted to trading on AIM under the ticker symbol KMK. 

Kromek has raised £15 million before expenses through the sale of new ordinary shares at a price of 51 pence per share in an oversubscribed fundraising. At admission, the Company will have a total of 107,607,335 ordinary shares in issue.

After the placing, Amphion holds an 11.6% equity stake in Kromek. 

Richard Morgan, Chief Executive Officer of Amphion and Chairman of Kromek, said: “We are pleased Kromek has completed a successful listing on AIM and has raised the capital required to support its commercial targets. This is an exciting point in Kromek’s development as it has substantial opportunities for growth. The listing and new capital will be important in securing further contracts for its leading technology in the medical imaging, security screening, and nuclear detection markets.”

 For further information on Amphion please contact:

Amphion Innovations                                   +1 212 210 6224
Charlie Morgan

Novella Communications                            +44 (0)20 3151 7008
Tim Robertson

Panmure Gordon                                          +44 (0)20 7866 2500
As Nominated Adviser and Broker
Corporate Finance:  Fred Walsh/ Freddy Crossley/ Grishma Patel
Broking:  Adam Pollock/ Charlie Leigh-Pemberton



This document does not constitute an offer to sell or solicitation to buy securities in the United States. Shares of Kromek may not be offered or sold in the United States without being registered under the United States Securities Act of 1933, as amended ("U.S. Securities Act") or based on an available exemption from such registration. The securities mentioned herein have not been and will not be registered under the U.S. Securities Act and no public offering of shares is being or will be made in the United States.

This communication is directed only at (i) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ("Order") (investment professionals) or (ii) persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations etc) (all such persons referred to above being "Relevant Persons"). Any investment activity to which this communication relates will only be available to and will only be engaged with Relevant Persons.


Kromek Group Plc
(“Kromek” or “the Company” or “the Group”)
Admission and First Day of Dealings on AIM

Kromek Group Plc (AIM: KMK), a UK based technology company, developing high performance materials and products for radiation detection, is pleased to announce that its shares will today be admitted to trading on AIM.

The Company has raised £15 million before expenses through the sale of new ordinary shares at a price of 51 pence per share in an oversubscribed fundraising. At admission, the Company will have a total of 107,607,335 ordinary shares in issue.

The proceeds of the fundraising will be used for product development, expansion of the sales and marketing team, investment into the Company’s intellectual property portfolio, capital expenditure to support future growth and manufacturing capability, working capital and strengthening the balance sheet, including paying down outstanding loans.


Arnab Basu, CEO, commented: “We are delighted with our oversubscribed fundraising. After many years developing the business and our technology, Kromek is ready to begin harvesting value by seizing the opportunities to sell our technology and products into the medical imaging, security screening and nuclear detection markets.

He added, “With the proceeds of the IPO, we will invest in the company’s IP portfolio and manufacturing capabilities, whilst accelerating our commercial activities in our chosen markets. We will continue to develop relationships with some of the world leading companies in our target sectors. We welcome our new shareholders and I look forward to working with them in order to achieve Kromek’s full potential.”

For further information and to download the Company’s Admission Document please visit  

Kromek Group Plc
Arnab Basu, CEO
Derek Bulmer, CFO

Tel: 01740 626060

Panmure Gordon
As Nominated Adviser and Broker

Investment Banking
Fred Walsh / Freddy Crossley / Grishma Patel

Corporate Broking
Adam Pollock / Charles Leigh-Pemberton

Tel: 020 7886 2500

Tavistock Communications
John West / Matt Ridsdale / Andrew Dunn

Tel: 020 7920 3150

Notes to Editors:

Kromek was incorporated in April 2003 in order to commercialise technology related to the development and manufacture of CZT and related materials which had been developed over a period of approximately 20 years in the Physics Department of Durham University, UK. In March 2004, the Company was awarded a Department of Trade and Industry SMART funding award for the construction of the first commercial crystal growth facility, and since then the Group has also been awarded the O2 Technology & Innovation Company of the year in 2006, 2007 and 2008; the IET Awards Innovation winner in 2008; the Global Security Challenge Security SME winner in 2009; and Arnab Basu, Group CEO, has been awarded the Ernst & Young UK Young Entrepreneur of the Year Award in 2009.

The Group’s strategy towards product development has been to take a project based approach, investing in specific areas where it has recognised a strong business opportunity for the deployment of its technology. Using its core CZT technology Kromek designs, develops and produces x-ray imaging and radiation detection products for the medical, security screening and nuclear markets.

Kromek has a portfolio of at least 70 granted patents and 110 pending applications. The Group’s products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

As part of the Group’s strategy to provide a vertically integrated technology offering, the Company acquired NOVA in June 2010 and eV Products in February 2013, both well established businesses based in the United States. California-based NOVA specialises in custom research and design, development, manufacturing, testing and marketing of ASICs and electronics for OEM components. Pennsylvania-based eV Products is a leading manufacturer of CZT-based detector technology, with its own IP portfolio as well as detailed know-how and existing customer relationships. eV Products develops and manufactures solid-state room temperature x-ray and gamma-ray detectors based on CZT. eV was acquired by Kromek to complement the Group’s IP, design and product development capabilities, strengthen its presence in key markets, and provide a permanent, physical presence in the USA, a strategically important market for the Group’s business.

Forward‑looking statements
Certain statements contained herein are forward looking statements and are based on current expectations, estimates and projections about the potential returns of the Group and industry and markets in which the Group will operate, the directors' beliefs and assumptions made by the directors. Words such as "expects", "anticipates", "should", "intends", "plans", "believes", "seeks", "estimates", "projects", "pipeline" and variations of such words and similar expressions are intended to identify such forward looking statements and expectations. These statements are not guarantees of future performance or the ability to identify and consummate investments and involve certain risks, uncertainties, outcomes of negotiations and due diligence and assumptions that are difficult to predict, qualify or quantify. Therefore, actual outcomes and results may differ materially from what is expressed in such forward looking statements or expectations. Among the factors that could cause actual results to differ materially are: the general economic climate, competition, interest rate levels, loss of key personnel, the result of legal and commercial due diligence, the availability of financing on acceptable terms and changes in the legal or regulatory environment.

This announcement has been prepared by Kromek Group Plc and is the sole responsibility of Kromek Group Plc. No liability whatsoever (whether in negligence or otherwise) arising directly or indirectly from the use of this announcement is accepted and no representation, warranty or undertaking, express or implied, is or will be made by Kromek Group Plc or Panmure Gordon (UK) Limited or any of their respective directors, officers, employees, advisers, representatives or other agents for any information or any of the opinions contained herein or for any errors, omissions or misstatements.

Any investment decision must be made solely on the basis of the admission document dated 10 October 2013 and any supplement thereto in connection with the admission of the ordinary share capital of Kromek Group Plc to trading on AIM.

The merits or suitability of any securities must be independently determined by the recipient on the basis of its own investigation and evaluation of Kromek Group Plc. Any such determination should involve, among other things, an assessment of the legal, tax, accounting, financial and other related aspects of the securities. Recipients of this announcement are recommended to seek their own independent legal, tax, financial and other advice and should rely solely on their own judgement, review and analysis in evaluating Kromek Group Plc and its securities.

Panmure Gordon (UK) Limited, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively as nominated adviser and broker to Kromek Group Plc and no one else in connection with the Placing and will not be responsible to anyone other than Kromek Group Plc for providing the protections afforded to customers of Panmure Gordon (UK) Limited or for providing advice in relation to the Placing.


About Amphion Innovations plc

Amphion (LSE: AMP) builds shareholder value in emerging companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.

On the web: